Optinose Announces Reporting Date for First Quarter 2022 Financial Results
05 mai 2022 17h00 HE
|
Optinose, Inc.
Conference Call and Webcast to be held May 12, 2022, at 8:00 a.m. Eastern Time YARDLEY, Pa., May 05, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients...
Optinose to Present at the Needham Virtual Healthcare Conference
08 avr. 2022 08h30 HE
|
Optinose, Inc.
YARDLEY, Pa., April 08, 2022 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Highlights
08 mars 2022 07h00 HE
|
Optinose, Inc.
Company reports fourth quarter and full year 2021 XHANCE net revenue of $22.5 million and $73.7 million Full year 2021 XHANCE prescriptions increased 28% compared to full year 2020 Company expects...
Optinose Reports Positive Top-line Results in ReOpen1, a Landmark Phase 3 Trial for XHANCE in Chronic Sinusitis
07 mars 2022 07h00 HE
|
Optinose, Inc.
XHANCE met both co-primary endpoints in the ReOpen1 trial, demonstrating statistically significant benefits on symptoms and CT scans in patients with chronic sinusitis There are no FDA-approved drug...
Optinose to Present at the Piper Sandler Virtual Healthcare Conference
23 nov. 2021 07h00 HE
|
Optinose, Inc.
YARDLEY, Pa., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced...
Optinose Reports Third Quarter 2021 Financial Results and Recent Operational Highlights
15 nov. 2021 16h26 HE
|
Optinose, Inc.
Third quarter 2021 XHANCE net revenue of $22 million increased 41% compared to third quarter 2020 Third quarter 2021 XHANCE prescriptions increased 25% from third quarter 2020 Conference call and...
Optinose Completes Patient Recruitment in Second Pivotal Trial for XHANCE in Chronic Sinusitis
28 oct. 2021 06h59 HE
|
Optinose, Inc.
Company Expects Top-Line Results in Second Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose Reports Second Quarter 2021 Financial Results and Recent Operational Highlights
11 août 2021 07h00 HE
|
Optinose, Inc.
Second quarter 2021 XHANCE net revenue of $18.4 million increased 79% compared to second quarter 2020 Second quarter 2021 XHANCE prescriptions increased 33% from second quarter 2020 Conference call...
Optinose Completes Patient Recruitment in Pivotal Trial for XHANCE in Chronic Sinusitis
30 juil. 2021 08h00 HE
|
Optinose, Inc.
Company Expects Top-Line Results in First Quarter 2022 XHANCE Reaches Important Milestone on Path to be the First FDA-Approved Drug Treatment for the Approximately 30 million Chronic Sinusitis...
Optinose Announces Reporting Date for First Quarter 2021 Financial Results and Upcoming Healthcare Conference Presentation
28 avr. 2021 08h30 HE
|
Optinose, Inc.
Conference Call and Webcast to be held May 5, 2021 at 8:00 a.m. Eastern Time Company to Present at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 YARDLEY, Pa., April 28, 2021...